An experimental coronavirus vaccine developed by Oxford University and drug manufacturer AstraZeneca appears to be up to 90% effective, the two partners announced Monday. The encouraging results co… ...

AstraZeneca and the University of Oxford announced Monday that late-stage trials show their COVID-19 vaccine was up to 90% effective in preventing the disease.

AstraZeneca and Oxford University have started developing a version of their coronavirus shot that targets omicron, as researchers study the efficacy of existing vaccines against the latest variant.

An illustration picture shows vials with COVID-19 Vaccine stickers attached and syringes with the logo of British pharmaceutical company AstraZeneca on November 17, 2020.

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

The AstraZeneca coronavirus vaccine trial, halted last week after an unexplained illness in one of the volunteers, will resume, the University of Oxford announced Saturday.

(Reuters) - AstraZeneca and Oxford University's COVID-19 vaccine is more effective when its second dose is given three months after the first, instead of six weeks, a peer-reviewed study published ...

More recent clinical trial results show AstraZeneca's COVID-19 vaccine is slightly less effective in stopping disease than the company first reported.

Oxford University says trials of a coronavirus vaccine that it is developing with pharmaceutical company AstraZeneca will resume, days after being paused due to a reported side-effect in a patient ...

An illustration picture shows vials with COVID-19 Vaccine stickers attached and syringes, with the logo of the University of Oxford and its partner British pharmaceutical company AstraZeneca, on ...

An illustration picture shows vials with Covid-19 Vaccine stickers attached and syringes, with the logo of the University of Oxford and its partner British pharmaceutical company AstraZeneca, on ...

The AstraZeneca coronavirus vaccine trial, halted last week after an unexplained illness in one of the volunteers, will resume, the University of Oxford announced Saturday.